# One Trial of JCXH-211 Intratumoral Injection Combined With Anti-PD-1 Antibody in Patients With Malignant Solid Tumors

> **NCT06781125** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Immorna Biotherapeutics, Inc.** · enrollment: 72 (estimated)

## Conditions studied

- Malignant Solid Tumors

## Interventions

- **DRUG:** JCXH-211 Intratumoral Injection Combined with Anti-PD-1 Antibody IV infusion

## Key facts

- **NCT ID:** NCT06781125
- **Lead sponsor:** Immorna Biotherapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-03-18
- **Primary completion:** 2028-03-30
- **Final completion:** 2028-06-30
- **Target enrollment:** 72 (ESTIMATED)
- **Last updated:** 2026-03-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06781125

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06781125, "One Trial of JCXH-211 Intratumoral Injection Combined With Anti-PD-1 Antibody in Patients With Malignant Solid Tumors". Retrieved via AI Analytics 2026-09-06 from https://api.ai-analytics.org/clinical/NCT06781125. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*